Long Term Safety of SPA100 (Fixed-dose Combination of Aliskiren/Amlodipine) in Patients With Essential Hypertension
Status:
Completed
Trial end date:
2012-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the long-term safety and tolerability of the
combination of aliskiren and amlodipine given to patients with essential hypertension. This
study is being conducted to support registration of the fixed combination of
aliskiren/amlodipine in the treatment for hypertension in Japan.